Taro Pharmaceutical Indus analyst ratings
Taro Pharmaceutical Indus analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/15/2022 | 57.3% | HC Wainwright & Co. | $73 → $54 | Maintains | Buy |
| 01/31/2022 | 112.64% | HC Wainwright & Co. | $75 → $73 | Maintains | Buy |
| 01/18/2022 | 118.47% | HC Wainwright & Co. | $82 → $75 | Maintains | Buy |
| 07/28/2021 | 138.86% | HC Wainwright & Co. | $80 → $82 | Maintains | Buy |
| 06/02/2021 | 133.03% | HC Wainwright & Co. | $81 → $80 | Maintains | Buy |
| 02/01/2021 | 135.95% | HC Wainwright & Co. | $80 → $81 | Maintains | Buy |
| 11/23/2020 | 133.03% | HC Wainwright & Co. | $82 → $80 | Maintains | Buy |
| 07/27/2020 | 138.86% | HC Wainwright & Co. | $96 → $82 | Maintains | Buy |
| 05/21/2020 | 179.64% | HC Wainwright & Co. | $94 → $96 | Reiterates | → Buy |
| 02/04/2020 | 173.81% | HC Wainwright & Co. | $110 → $94 | Maintains | Buy |
| 03/12/2018 | 261.2% | HC Wainwright & Co. | → $124 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/15/2022 | 57.3% | HC Wainwright & Co. | 73 美元 → 54 美元 | 维护 | 买 |
| 01/31/2022 | 112.64% | HC Wainwright & Co. | 75 美元 → 73 美元 | 维护 | 买 |
| 01/18/2022 | 118.47% | HC Wainwright & Co. | 82 美元 → 75 美元 | 维护 | 买 |
| 2021 年 7 月 28 日 | 138.86% | HC Wainwright & Co. | 80 美元 → 82 美元 | 维护 | 买 |
| 06/02/2021 | 133.03% | HC Wainwright & Co. | 81 美元 → 80 美元 | 维护 | 买 |
| 2021 年 1 月 2 日 | 135.95% | HC Wainwright & Co. | 80 美元 → 81 美元 | 维护 | 买 |
| 11/23/2020 | 133.03% | HC Wainwright & Co. | 82 美元 → 80 美元 | 维护 | 买 |
| 07/27/2020 | 138.86% | HC Wainwright & Co. | 96 美元 → 82 美元 | 维护 | 买 |
| 05/21/2020 | 179.64% | HC Wainwright & Co. | 94 美元 → 96 美元 | 重申 | → 购买 |
| 02/04/2020 | 173.81% | HC Wainwright & Co. | 110 美元 → 94 美元 | 维护 | 买 |
| 03/12/2018 | 261.2% | HC Wainwright & Co. | → 124 美元 | 启动覆盖范围开启 | → 购买 |
Taro Pharmaceutical Indus Questions & Answers
太郎药业行业问题与解答
The latest price target for Taro Pharmaceutical Indus (NYSE: TARO) was reported by HC Wainwright & Co. on August 15, 2022. The analyst firm set a price target for $54.00 expecting TARO to rise to within 12 months (a possible 57.30% upside). 3 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2022年8月15日公布了太郎药业（纽约证券交易所代码：TARO）的最新目标股价。该分析公司将目标股价定为54.00美元，预计TARO将在12个月内升至12个月内（可能上涨57.30％）。去年有3家分析公司公布了评级。
The latest analyst rating for Taro Pharmaceutical Indus (NYSE: TARO) was provided by HC Wainwright & Co., and Taro Pharmaceutical Indus maintained their buy rating.
HC Wainwright & Co. 对太郎药业（纽约证券交易所代码：TARO）的最新分析师评级由HC Wainwright & Co. 提供，太郎药业集团维持买入评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Taro Pharmaceutical Indus, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Taro Pharmaceutical Indus was filed on August 15, 2022 so you should expect the next rating to be made available sometime around August 15, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与太郎制药工业公司的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。太郎药业集团的最新评级是在2022年8月15日发布的，因此您应该预计下一个评级将在2023年8月15日左右公布。
While ratings are subjective and will change, the latest Taro Pharmaceutical Indus (TARO) rating was a maintained with a price target of $73.00 to $54.00. The current price Taro Pharmaceutical Indus (TARO) is trading at is $34.33, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但太郎制药业（TARO）的最新评级维持不变，目标股价为73.00美元至54.00美元。太郎制药业（TARO）目前的交易价格为34.33美元，超出了分析师的预期区间。